Gonadotropin-releasing hormone agonist for the preservation of ovarian function in survivors of haematopoietic stem cell transplantation for haematological diseases

Table 2 Number of POI after HSCT and RR at 95% CI (patients with GnRHa treatment or without it)

	GnRHa	Control	Total	RR(95%CI)^a	P
POI	84(78.50)	170(83.33)	254(81.67)	1.29(0.80–2.07)	0.293
Not POI	23(21.50)	34(16.67)	57(18.33)
Total	107	204	311

^aThere was no statistical significance even after adjusting for factors. (RR: 1.20, 95% CI: 0.74–1.95, P = 0.465), adjusted for conventional chemotherapy prior to the myeloablative regimen for HSCT; (RR: 1.27 95% CI: 0.79–2.05, P = 0.322), adjusted for TBI exposure; (RR: 1.19, 95% CI: 0.73–1.93, P = 0.487), adjust for above two factors simultaneously

ISSN: 1472-6874